Anzeige
Mehr »
Lynx Broker
Login
Montag, 14.10.2019 Börsentäglich über 12.000 News von 613 internationalen Medien
Investoren zahlen Prämie: Fura Gems schließt Kapitalrunde über 26,8 Mio. CAD ab
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DPC0 ISIN: NO0010650013 Ticker-Symbol: 7BG 
Frankfurt
14.10.19
15:34 Uhr
1,438 Euro
-0,016
-1,10 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BERGENBIO ASA Chart 1 Jahr
5-Tage-Chart
BERGENBIO ASA 5-Tage-Chart

Aktuelle News zur BERGENBIO Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
Börsennews zur BERGENBIO Aktie und weiteren Hot Stocks erhalten
02.10.BerGenBio to Present Clinical Data From Phase II Trial With Selective AXL Inhibitor at 34th Annual SITC Meeting201BERGEN, Norway, Oct. 2, 2019 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications...
► Artikel lesen
27.09.BerGenBio Presents Phase II Trial Updates with Selective AXL Inhibitor Bemcentinib at the European Society for Medical Oncology (ESMO) 2019 Congress296BERGEN, Norway, Sept. 27, 2019 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer...
► Artikel lesen
09.09.BerGenBio Presents Phase II Trial Updates With Selective AXL Inhibitor Bemcentinib in Non-Small Cell Lung Cancer at 2019 World Conference on Lung Cancer346BERGEN, Norway, Sept. 9, 2019 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer...
► Artikel lesen
19.08.BergenBio reports Q2 results-
19.08.BerGenBio ASA: Results for the Second Quarter and First Half 2019194- Acute Myeloid Leukaemia (AML): Preliminary Phase II clinical shows promising efficacy for bemcentinib in combo with low-intensity chemo in elderly AML patients unfit for intensive therapy -...
► Artikel lesen
20.06.EuroBiotech Report-Sanofi cuts, AstraZeneca in Korea, uniQure M&A, U.K. and BerGenBio18
14.06.BerGenBio posts updated data on trial of elderly AML patients-
14.06.BerGenBio to present clinical data at EHA-
14.06.BerGenBio Presents Preliminary Phase II Clinical Data at EHA 24: Bemcentinib in Combination With Low Dose Chemotherapy Yields Durable Responses in AML Patients Unfit for Intensive Chemotherapy35OSLO, Norway, June 14, 2019 /PRNewswire/ -- Two posters to be presented at the 2019 annual congress of the European Hematology Association on 14th June Phase II trial evaluating bemcentinib...
► Artikel lesen
03.06.BerGenBio Presents New Phase II Clinical Data That Bemcentinib in Combination With Low Dose Chemotherapy Improves Efficacy and Duration of Survival in Elderly AML Patients at ASCO 201919CHICAGO, June 3, 2019 /PRNewswire/ -- Phase II trial evaluating bemcentinib in combination with low-intensity chemotherapy in elderly AML patients unfit for intensive therapy shows promising...
► Artikel lesen
02.06.BerGenBio Presents New Preliminary Clinical and Biomarker Data Showing Durable Response & Median Survival Rates in Phase II Trial With Bemcentinib and KEYTRUDA in Pts With Advanced NSCLC at ASCO 201958CHICAGO, June 2, 2019 /PRNewswire/ -- Phase II trial evaluating bemcentinib in combination with KEYTRUDA in advanced NSCLC patients shows 12-month survival data surpassing historical...
► Artikel lesen
16.05.BerGenBio to Present New NSCLC and AML Clinical Data and Biomarker Data From Phase II Development Programme With Selective AXL Inhibitor Bemcentinib at ASCO 201923BERGEN, Norway, May 15, 2019 /PRNewswire/ -- Two peer reviewed abstracts on Phase II clinical data with bemcentinib accepted for presentation at ASCO 2019Non-Small-Cell Lung Cancer...
► Artikel lesen
08.05.BerGenBio Completes Recruitment Into Second Stage of Phase II Trial With Selective AXL inhibitor bemcentinib in Combination with KEYTRUDA in Patients With Advanced NSCLC22Phase II, Simon two-stage trial evaluating bemcentinib and KEYTRUDA in previously treated NSCLC post chemotherapy (Cohort A, NCT03184571) First stage previously met efficacy endpoint Second...
► Artikel lesen
08.05.BergenBio reports Q1 results-
08.05.BerGenBio ASA: Results for the First Quarter 201930- Advanced leukaemia (AML/MDS): Phase II trial fully recruited and combination trial with low-intensity chemotherapy meets efficacy endpoint in hard to treat relapsed / refractory (R/R) leukaemia -...
► Artikel lesen
24.04.BerGenBio ASA: Invitation to First Quarter Presentation and Webcast21BERGEN, Norway, April 24, 2019 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), will announce its results for the first quarter on Wednesday, 8 May 2019. A presentation by BerGenBio's senior management...
► Artikel lesen
23.04.BerGenBio to Present NSCLC and AML Clinical Data From Phase II Development Programme With Selective AXL Inhibitor Bemcentinib at ASCO 201940- Phase II data in AML combining bemcentinib with low-dose chemotherapy and NSCLC combining with KEYTRUDA - Accepted for presentation at ASCO in June 2019 OSLO, Norway, April...
► Artikel lesen
09.04.BerGenBio to Present at H.C. Wainwright Global Life Sciences Conference20BERGEN, Norway, April 9, 2019 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class drug candidates targeting...
► Artikel lesen
02.04.BerGenBio Extends Phase II Trial With Bemcentinib and KEYTRUDA in NSCLC to Include Patients With Disease Progression on Immune Checkpoint Inhibitor Therapy29- First patient dosed in new cohort of Phase II trial evaluating selective AXL inhibitor bemcentinib in combination with KEYTRUDA in patients with advanced NSCLC whose disease is progressing...
► Artikel lesen
02.04.BerGenBio: Preclinical Data Presented at AACR Reinforces Bemcentinib's Potential to Reverse Tumour Immunosuppression and Therapy Resistance55Extensive data in pre-clinical models of non-small cell lung cancer (NSCLC) and pancreatic cancer demonstrating AXL's role in reversing tumour-mediated immunosuppression and therapy resistance...
► Artikel lesen
Seite:  Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1